Biology of cancer metastasis;Spredning av kreftsvulster

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 8, 1996, Pages 952-957

  Berner, Aasmund ^a   Bryne, Magne ^a   Thrane, Per S ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE;

CELL TRANSFORMATION; CELLULAR IMMUNITY; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNITY, CELLULAR; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 0030594152     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 517-73.
2. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eight G.H.A. Clouves Memorial Award Lecture. Cancer Res 1990; 50: 6130-8.
3. Fodstad Ø, Kjønniksen I. Microenvironment revisited: time for reapproval of some prevailing concepts of cancer metastasis. J Cell Biochem 1994; 56: 23-8.
4. Ewing J. Neoplastic diseases. 6. utg. Philadelphia: Saunders, 1928.
5. Fidler IJ, Kripke ML. Metastasis results from pre-existing variant cells within a malignant tumor. Science 1977; 197: 893-5.
6. Fidler IJ. Cancer metastasis. Br Med Bull 1991; 47: 157-77.
7. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
8. Baserga R. Oncogenes and the strategy of growth factors. Cell 1994; 79: 927-30.
9. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8.
10. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995; 1: 27-30.
12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9.
13. Weidner N. Intratumor microvessela density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
14. Tarin D, Price JE, Kettlewell MGW, Souter RG, Vass ACR, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984; 44: 3584-92.
15. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995; 1: 149-53.
16. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastatses by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
17. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-I. Science 1994; 265: 1582-4.
18. Shurmann GM, Bishop AE, Facer P, Vecchio M, Lee K, Rampton DS et al. Increased expression of cell adhesion molecule P-selectinin active in inflammatory bowel disease. Gut 1995; 36: 411-8.
19. Stetler-Stevenson WG, Aznanoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73.
20. Hart IR, Saini A. Biology of tumor metastasis. Lancet 1992; 339: 1453-7.
21. Stracke ML, Murata J, Aznavoorian S, Liotta LA. The role of extracellular matrix in tumor cell metastasis. In Vivo 1994; 8: 49-58.
22. Garrigues J, Anderson J, Hellström KE, Hellström I. Antitumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes. J Cell Biol 1994; 125: 129-42.
23. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. 3. utg. New York: Garland, 1994.
24. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
25. Miyasaka M. Cancer metastasis and adhesion molecules. Clin Orthop 1995; 312: 10-8.
26. Mitjans F, Sander D, Adàn J, Sutter A, Martinez JM, Jäggle C-S et al. An anti-av-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Science 1995; 108: 2825-38.
27. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
28. Matsumara Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340: 1053-8.
29. Tarin D, Matsumara Y. Deranged CD44 gene activity in malignancy. J Pathol 1993; 171: 249-50.
30. Wielenga VJM, Heider K-H, Offerhaus GJA, Adolf GR, van den Berg FM, Ponta H et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-6.
31. Tarin D, Matsumara Y. Recent advances in the study of tumour invasion and metastasis. J Clin Pathol 1994; 47: 385-90.
32. Matsumara Y, Sugiyama M, Matsumara S, Hayle AJ, Robinson P, Smith JC et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995; 177: 11-20.
33. Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki BM. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin on intratumoral vessels. J Natl Cancer Inst 1995; 87: 366-71.
34. Zetter BR. Adhesion molecules in tumor metastasis (see comments). Semin Cancer Biol 1993; 4: 219-29.
35. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993; 68: 4-17.
36. Mattijssen V, Peters HM, Schalkwijk L, Manni JJ, van Hof-Grootenboer B, de Mulder PH et al. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int J Cancer 1993; 55: 580-5.
37. Jørgensen T, Berner Aa, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Upregulation of the oligosaccharide Sialyl-LewisX. A new prognostic parameter in metastatic prostate cancer. Cancer Res 1995; 55: 1817-9.
38. Bryne M, Åsheim HC, Giercksky KE. Blokkering av karbohydratadhesjon. Et nytt prinsipp for behandling av maligne tilstander? Tidsskr Nor Lægeforen 1995; 115: 1957-60.
39. Chammas R, Veiga SS, Travassos LR, Brentani RR. Functionally distinct roles for glycosylation of alpha and beta integrin chains in cell-matrix interactions. Proc Natl Acad Sci USA 1993; 90: 1795-9.
40. Labarriere N, Piau JP, Otry C, Dennis M, Lustenberger P, Meflah K et al. H blood group antigen carried by CD44 modulates tumorigenicity of rat colon carcinoma cells. Cancer Res 1994; 54: 6275-81.
41. Hudson DL, Sleeman J, Watt FM. CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci 1995; 108: 1959-70.
42. Higging LF. Flip-flop: the transmembrane translocation of lipids. Cell 1994; 79: 393-5.
43. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
44. Cromme FV, van Bommel PFJ, Walboomers JMM, Gallee MPW, Stern PL, Kenemans P et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69: 1176-81.
45. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PI. Natural history of HLA expression during tumour development. Immunology Today 1993; 14: 491-9.
46. Weiss L. Biomechanical interactions of cancer cells with the microvasculature during hematogenous metastasis. Cancer Metastasis Rev 1992; 11: 227-35.
47. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884-6.